'Anakinra inhibited NFκB activation in CLL cells in part by lowering oxidative stress and led to transient tumor regression in patients. However, IFN signaling became up-regulated and was associated with loss of the initial clinical response.'

https://www.pnas.org/doi/10.1073/pnas.2405644121